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REVIEW
On the role of the cellular prion protein in the uptake and signaling of 
pathological aggregates in neurodegenerative diseases
Giuseppe Legname and Carlo Scialò
Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore Di Studi Avanzati (SISSA), Trieste, Italy
ABSTRACT
Neurodegenerative disorders are associated with intra- or extra-cellular deposition of aggregates 
of misfolded insoluble proteins. These deposits composed of tau, amyloid-β or α-synuclein spread 
from cell to cell, in a prion-like manner. Novel evidence suggests that the circulating soluble 
oligomeric species of these misfolded proteins could play a major role in pathology, while 
insoluble aggregates would represent their protective less toxic counterparts. Recent convincing 
data support the proposition that the cellular prion protein, PrPC, act as a toxicity-inducing 
receptor for amyloid-β oligomers. As a consequence, several studies focused their investigations 
to the role played by PrPC in binding other protein aggregates, such as tau and α-synuclein, for its 
possible common role in mediating toxic signalling. The biological relevance of PrPC as key ligand 
and potential mediator of toxicity for multiple proteinaceous aggregated species, prions or PrPSc 
included, could lead to relevant therapeutic implications. Here we describe the structure of PrPC 
and the proposed interplay with its pathological counterpart PrPSc and then we recapitulate the 
most recent findings regarding the role of PrPC in the interaction with aggregated forms of other 
neurodegeneration-associated proteins.
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1. Introduction
Neurodegenerative disorders are characterized by 
the progressive failure of specific subsets of neurons 
associated with intra- or extra-cellular deposition of 
insoluble protein aggregates [1]. Extracellular depos-
its include aggregates with immunoreactivity for 
amyloid-β (Aβ) or prions (PrPSc), while intracellular 
deposits include tau and α-synuclein (α-syn). 
Alzheimer’s disease (AD) is characterized by the 
progressive accumulation of extracellular pathologi-
cal-associated plaques of Aβ and the presence of 
intracellular neurofibrillary tangles of hyperpho-
sphorylated microtubule-associated protein tau 
[2,3]. In addition to AD, tau pathology or tauopa-
thies include frontotemporal dementia linked to 
chromosome 17 (FTLD-17), progressive supranuc-
lear palsy (PSP), argyrophilic grain disease (AGD), 
corticobasal degeneration (CBD) and Pick’s disease 
[4]. Lewy bodies (LB) and Lewy neurites (LN), char-
acteristics of Parkinson’s disease (PD) and dementia 
with Lewy bodies (DLB), are mainly composed of 
aggregated α-syn, while oligodendroglial and neuro-
nal α-syn deposits are present in multiple system 
atrophy (MSA) [5,6]. Prion diseases, or transmissi-
ble spongiform encephalopathies (TSEs), are unique 
infectious transmissible neurodegenerative disorder 
[7,8] with no clear evidence of naturally occurring 
human-to-human transmission of other neurode-
generative conditions [9,10]. Despite this distinc-
tion, clinical, cellular, molecular and biochemical 
studies provided evidence supporting a common 
mechanism of spreading and propagation of the 
neurodegenerative process [11–14]. The prion-like 
term is used to both indicate the similarities with 
the prion replication and propagation process and 
the lack of infectivity. The canonical model for the 
replication of misfolded protein lies in the prion 
paradigm [15]. In prion disorders, the conversion 
of the physiological normal cellular prion protein 
(PrPC) into its β-sheet enriched pathological con-
former PrP-scrapie (PrPSc) is central to the disease 
[16]. According to the prion-like hypothesis, mis-
folded protein assemblies in neurodegenerative dis-
eases other than prion disorders, act as seeds of 
aggregation that can recruit their native isoforms 
and convert them into pathological molecules. The 
seed indicates the smallest amount of a misfolded 
protein which, once released in the extra-cellular 
space, is able to template and impose the patholo-
gical conversion onto native molecules and subse-
quently spread throughout connected brain areas 
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[13]. Pathological investigations, genetic discoveries, 
animal and biophysics prediction models all sup-
ported a strict connection between pathologic pro-
tein aggregates and neurodegenerative diseases [17]. 
Emerging evidence has suggested that circulating 
soluble oligomers could play a role in the patholo-
gical process, while insoluble aggregates would 
represent protective less toxic counterparts [4,17–-
17–27]. Accordingly, the severity of cognitive defi-
cits in AD correlates more strongly with the levels 
of soluble forms of Aβ than with insoluble amyloid 
plaque load [26] and impairment of hippocampal 
synaptic plasticity is detected before the formation 
of insoluble Aβ plaques in amyloid-β precursor pro-
tein (APP) transgenic mouse models of AD [28]. 
Moreover, soluble Aβ oligomers have shown detri-
mental effects on hippocampal long-term potentia-
tion (LTP) in vitro and in vivo [26]. Similar effects 
have been shown for tau oligomers, either synthetic 
or extracted from AD diseased brains [21,29] and 
for in vitro obtained α-syn oligomers [30–32]. Aβ 
oligomers have been the most extensively investi-
gated pathological species with multiple ligands 
identified [27]. Among these, PrPC is the most pro-
minent [33–38] and has been recently recognized as 
the highest affinity binding partner for Aβ oligo-
mers [39]. Several studies have revealed that the 
binding between PrPC and Aβ oligomers occurs at 
sub-nanomolar affinity interaction [19,34,35,37,40–-
,37,40–46]. However, other studies have shown PrP- 
independent Aβ oligomer effects [47–50]. The 
hypothesis that PrPC, central in the pathogenesis of 
prion disorders, could represent a common acceptor 
for multiple neurodegeneration-associated protein 
species, has stimulated further investigations. As 
a consequence, in recent years the interplay between 
PrPC and oligomers of proteins other than Aβ, such 
as tau and α-syn, has been increasingly investigated 
[19,22,23,51–55]. A possible interaction between tau 
and PrPC was already suggested by neuropathologi-
cal examinations of Gerstmann-Straüssler-Scheinker 
syndrome (GSS) cases, a subset of familial forms of 
TSEs. Mutant PrP assemblies display co-pathology 
with hyperphosphorylated forms of tau in GSS cases 
[56–63]. The nature of this co-pathology is still 
a matter of debate and further studies on the mole-
cular interplay between PrPC and tau could shed 
new light in the understanding of this phenomenon. 
Here we first describe the structure of PrP and the 
hypothesized interplay with its pathological counter-
part, PrPSc, and then we will recapitulate the most 
relevant discoveries regarding the role of PrPC in 
the interaction with aggregated forms of several 
neurodegeneration-associated proteins.
2. The prion protein structure and 
PrPC-mediated PrPSc toxicity
2.1 Prion protein structure
The cellular form of the prion protein, PrPC, is 
a glycosylphosphatidylinositol (GPI)-anchored protein 
of 231 amino acids encoded in humans by the PRNP 
gene located on chromosome 20 [64–68]. The protein is 
structured in two regions: 1) an N-terminal flexible tail 
and 2) a globular C-terminal domain containing 3 α- 
helices and 2 short β-strands flanking the first α-helix. 
Recently, a third beta sheet strand has been described 
suggesting that the protein can adopt a more elaborate 
β0-β1-α1-β2-α2-α3 structural organization than the cano-
nical β1-α1-β2-α2-α3 fold [69]. The flexible tail is further 
divided in a small charged cluster, an octarepeat (OR) 
region and a central domain, which comprises a second 
charged cluster and a hydrophobic domain (HD). The 
protein is translocated to the endoplasmic reticulum 
where it undergoes several post-translational modifica-
tions including N-linked glycosylation at residues N181 
and N197, formation of a single disulphide bond at posi-
tion C179 and C214, cleavage of the C-terminal signal 
peptide and subsequent attachment of the GPI anchor at 
position 231 [70]. PrPC is widely expressed in the CNS 
during early development, in adult neurons and glial cells. 
Several putative functions have been suggested for PrPC, 
including ion balance homoeostasis, neuritogenesis, neu-
ronal homoeostasis, cell signalling, cell adhesion and 
a protective role against stress [71]. PrPC could serve as 
a dynamic platform for signalling modules at the cell 
surface, acting with the properties of a cell surface scaffold 
protein [72]. Since PrPC does not span the plasma mem-
brane, accessory molecules are required to transduce sig-
nals into the cytosol. Several PrPC binding partners have 
been identified so far. The most studied are the metabo-
tropic glutamate receptors (mGluR1 and mGluR5) via 
laminin γ1 chain interaction [73], the α7 type of nicotinic 
acetylcholine receptor (α7nAChR) following the binding 
of the cochaperone hop/STI1 [74], the neural cell adhe-
sion molecule (NCAM) [75] and the Laminin Receptor 
Precursor/Laminin Receptor (LRP/LR) [76].
2.2 PrPC is essential for prion replication
Several studies have shown that the expression of PrPC 
is essential for prion propagation. Knock-out mouse 
models for PrPC are resistant to prion diseases and to 
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the propagation of the scrapie infectious agent [77]. In 
a seminal study, neural tissue overexpressing PrPC was 
grafted into the brain of PrP-deficient mice, which were 
later inoculated with infectious prions. PrPC deficient 
neurons, exposed to PrPSc material produced by PrPC 
over-expressing neuronal grafts, did not show neuro-
pathological alterations [78]. In another study it was 
shown that depleting endogenous neuronal PrPC in 
mice with established prion infection reverted early 
spongiform changes and prevented neuronal loss and 
progression to clinical disease [79]. The expression of 
physiological levels of a form of PrPC devoid of the GPI 
anchor (∆GPI-PrP) was permissive for PrPSc replica-
tion but produced a clinically silent phenotype [80]. 
When ∆GPI-PrP was expressed at higher levels it pro-
duced a late onset spontaneous phenotype associated 
with the deposition of large amyloid plaques of PrPSc. 
Interestingly, disease onset was accelerated by co- 
expression of wild-type (WT) full-lenght PrPC [81].
2.3 PrPC mediates PrPSc toxicity
All the afore-mentioned studies, in addition to con-
firming the role of PrPC as an essential substrate for 
prion replication, indicated PrPC as the cellular media-
tor of PrPSc neurotoxic effects. Moreover, different 
studies have suggested that PrPC can acquire 
a neurotoxic role in the absence of PrPSc/prion propa-
gation [82,83]. A mouse model expressing a PrP 
mutant with a deletion of its hydrophobic domain 
(PrP∆HD) has shown that neurotoxicity of this dele-
tion mutant was linked to a PrPC-dependent signalling 
pathway [83–85]. Importantly, these phenotypes were 
suppressed in a dose-dependent manner by co- 
expression of WT PrPC, suggesting that WT and 
mutated molecules could interact with each other, or 
compete for binding to a common molecular target that 
mediated both physiological and pathological effects. 
These toxic mutants of PrPC induced spontaneous 
ionic currents, recordable by patch clamping techni-
ques, when expressed in cell lines [86] and in primary 
neurons [87]. Notably, also these currents were silenced 
by co-expression of WT PrPC in the same cells. Further 
studies of PrP∆HD mutants and their toxicity have 
suggested the presence of an auto-inhibitory mechan-
ism that regulates the functional activity of PrPC, 
mediated by an intramolecular docking between N- 
and C-terminal domains of PrPC [88]. According to 
this model, the toxic activity of the flexible N-terminal 
domain is regulated in cis by the globular structured 
C-terminal domain and anti-PrP antibodies directed 
against the C-terminal domain would produce 
a neurotoxic effect by disrupting this interaction. The 
authors of this study suggested that the same effect 
could be mediated by PrP pathological ligands, such 
as PrPSc or circulating pathological oligomers (Figure 
1) [88]. Even if this model provides an interesting 
mechanistic explanation for oligomer-induced PrPC 
mediated neurotoxicity, the fact that mice expressing 
N-terminally truncated PrPC remained susceptible to 
prion diseases [89,90] argues against this being 
a primary pathogenic mechanism. Other studies have 
shown that PrPSc produced and released by ScN2a 
cronically infected cells induced apoptosis in SH-SY5Y 
cells, only when cells were transienly transfected to 
express PrPC [82]. The scrapie prion-induced cell 
death was paralleled by the activation of the Jun 
N-terminal kinase (JNK) [82]. It should be stressed 
that the authors did not characterize whether the 
toxic PrPSc molecules were a PK-resistant intermediate 
generated during the conversion process or oligomers 
or fibrils. The same group repeated the experiment 
expressing heterologous PrPC molecules, less suceptible 
to prion conversion due to species barrier. 
Heterologous PrPC, be it of hamster, human, cervid or 
bovine origin, efficiently mediated toxic signalling of 
mouse PrPSc [43]. Furthermore, they showed that PrPSc 
neurotoxic activity in SH-SY5Y cells expressing PrPC 
can be reduced by the use of the oligomer-specific 
antibody A11 [43]. A similar PrPC-mediated neurotoxic 
effect was observed in the same experimental settings 
with Aβ oligomers [43].
2.4 PrPC proteolytic cleavage and its role in 
pathology
PrPC is subject to post-translational proteolytic proces-
sing. These cleavage events have been shown to be 
involved in the regulation of its physiological functions, 
to produce biologically active fragments and to poten-
tially influence pathology. Four cleavages appear to be 
conserved and currently represent the best investigated 
processing events on PrPC [91,92]. The first proteolytic 
processing takes place in a region termed α-cleavage 
(located at positions K110/H111 or H111/M112 in the 
human sequence) and releases the N-terminal flexible 
part of PrPC (N1 fragment of ~11 kDa) while leaving 
the globular C-terminal domain (C1 fragment of ~ 16 
kDa) attached to the membrane via its GPI anchor 
[91–93]. Another minor proteolytic event termed β- 
cleavage occurs at residues 90–91. In consequence of 
this cleavage, an N-terminal fragment of ~ 9 kDa 
(termed N2) is released whereas a corresponding C2 
fragment of 18–20 kDa (depending on the glycosylation 
status) remains bound to the cellular membrane. In 
contrast to α-cleavage, β-cleavage is mainly observed 
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Figure 1. Schematic representation of the major features involved in the complex interplay between PrPC and toxic pathological 
aggregates.
Panel A represents all potential deleterious interactions between PrPC, PrPSc and toxic pathological aggregates. (1) PrPC is involved in the 
uptake and internalization of tau and α-syn fibrils [51,52]. (2) The interaction between PrPSc and PrPC is necessary for prion replication [77] 
and is also the driver of PrPSc-induced toxic signalling [43], mediated by PrPC via several putative binding partners (5) [109]. (3) An auto- 
inhibitory mechanism regulates the functional activity of PrPC, mediated by an intra-molecular docking between N- and C-terminal domains 
of PrPC [88]. Anti-PrPC antibodies directed against PrPC C-terminal domain (3) or PrPC toxic ligands (4) produce a neurotoxic effect by 
disrupting this intra-molecular interaction. (4) PrPC mediates Aβ, tau and α-syn aggregates neurotoxic effects via two binding sites located 
in its N-terminus [19,40,43,46] (5) PrPC mediates cell signalling acting as an extracellular scaffolding protein, able to organize multiprotein 
complexes at the cell surface [72] (6) Toxic Aβ oligomers could bind directly to the cell membrane and disrupt its normal function, leading 
to cytotxicity [96]. N1 could bind to these species, or to the membrane surface, in a manner that prevents the formation of cell membrane 
damage (not shown). The B panel describes some of the hypothesized protective effects of PrPC cleavage events and of anti-PrPC antibodies. 
(7) PrPC α-cleavage and shedding protective role: both the released N1 fragment and shed-PrP contain the N-terminal part of the protein 
harbouring binding sites for toxic aggregates, so, they could bind and neutralize them. The same effect could be induced by aggregate- 
directed neutralizing antibodies (in purple) [43]. Cleavage events decrease the presence of PrPC at the cell membrane impeding the 
transmission of aggregate-induced toxic response(s). In prion disorders, cleavage events would reduce the amount of PrPC which could be 
converted in PrPSc [92]. (8) Antibodies directed against the N-terminus of PrPC showed a protective role against PrPC-mediated neurotoxic 
signalling, probably competing with toxic aggregates on their binding sites [22,23,35,110] 
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under pathological conditions and much less present or 
even absent in normal conditions. A third physiological 
cleavage of PrPC occurs in close proximity to the GPI- 
anchor and results in the release of the almost full- 
length protein (shed-PrP) from the plasma membrane 
[91,92,94]. Recently, another proteolytic event of PrPC, 
i.e. γ-cleavage, has been characterized and described 
[95]. The exact cleavage site remains to be identified, 
but the molecular weights of the resulting fragments 
(i.e. a released N-terminal fragment N3 of ~ 20 kDa 
and a small GPI-anchored C3 fragment of ~ 5 kDa), 
suggest cleavage in a region between aa 170 and 200, 
possibly just N-terminal of the first N-glycosylation 
site. γ-cleavage seems to occur preferentially on ungly-
cosylated PrPC in the Golgi and trans-Golgi network as 
well as the endocytic recycling compartment and to be 
mediated by a metalloprotease [95]. Even if its patho-
physiological roles are still unclear, the identification of 
the C3 fragment in Creutzfeldt–Jakob disease (CJD) 
brain samples suggests a possible link with pathology 
[92,95]. Several reports have highlighted the impor-
tance of α-cleavage to regulate PrPC physiological func-
tions [91,92], a detailed description of which goes 
beyond the scopes of this review. We will briefly discuss 
only those shown to have a potential influence in the 
interaction between PrPC and pathological aggregates 
of proteinaceous species, PrPSc included. At least two 
modes of how proteolytic processing of PrPC plays 
a role in disease have been suggested. First, both the 
released N1 fragment and shed-PrP contain the 
N-terminal part of the protein, which is thought to 
interact with pathological assemblies. Once released, 
they could bind and neutralize them. Second, cleavage 
events would decrease the presence of PrPC at the cell 
membrane, thus impeding the transmission of aggre-
gate-induced toxic response(s) as well as reducing the 
substrate for the conversion of PrPC in PrPSc, in prion 
disorders (Figure 1) [92]. Accordingly, the N1 fragment 
showed neuroprotective properties against PrPSc [43] 
and Aβ-mediated synaptic damage [34,96,97] and both 
PrPC shedding and α-cleavage are increased during AD 
[98] (see next paragraph). Finally, since the N-terminal 
fragment is relevant for PrPC internalization [99], its 
cleavage will result in an increased retention of the C1 
fragment on the cell membrane. This has several ben-
eficial effects. In fact, the C1 fragment cannot be con-
verted in PrPSc and was also shown to act as 
a dominant negative inhibitor of PrPC pathological 
conversion, further preventing PrPSc replication 
[100,101].
3. PrPC-mediated Aβ toxicity
3.1 Aβ oligomers and AD heterogeneity
Aβ pathological deposits encompass a mixture of pep-
tides with different solubility, stability and biological 
properties [27], which can be present either in different 
areas of a single AD affected brain or in patients suffer-
ing from various subtypes of AD [102,103]. The hetero-
geneity in the length of Aβ peptides is related to 
different γ-secretase C-terminal cleavage positions in 
the amyloid precursor protein (APP). In fact, γ- 
secretase generates several peptides, of which Aβ43, 
Aβ42, Aβ40, Aβ38 and Aβ37 variants are the most 
abundant and studied (Aβ numbering indicates the 
last C-terminal amino-acid residue) [27]. Additional 
heterogeneity is generated by enzymatic processes 
mediated by aminopeptidases, glutaminylcyclases or 
isomerases, resulting in more than 20 Aβ peptides 
that participate in putative Aβ functions in the normal 
brain and oligomerization and fibrillization in the AD 
affected brain [27]. Aβ monomers do not interrupt 
normal synaptic function, whereas small Aβ oligomers 
and large Aβ aggregates (protofibrils) impair synaptic 
plasticity [26]. These different pathologic Aβ oligomeric 
circulating species likely contribute to the heterogeneity 
of AD clinical manifestations [104–107]. Aβ oligomers 
can be either obtained by in vitro aggregation of syn-
thetic Aβ monomers or by collection from the culture 
medium of specific cell lines or from the soluble frac-
tion of AD diseased brains [26].
3.2 PrPC as Aβ oligomer receptor
Aβ oligomers have been shown to act as neurotoxins 
[24,26] with several putative ligands/receptors [27]. 
Among potential receptors, PrPC has been extensively 
studied and has been recently recognized as the highest 
affinity binding partner for Aβ oligomers [39]. The first 
indication of PrPC and Aβ oligomer interaction was 
obtained using an unbiased expression cloning screen-
ing approach for a specific class of Aβ42 synthetic 
oligomers, namely Aβ-derived diffusible ligands 
(ADDLs) [37]. ADDLs binding affinity to PrPC was 
claimed in the nanomolar scale and the ADDLs- 
mediated blockade of LTP was absent in hippocampal 
slices from young adult PrP null mice. In addition, 
anti-PrP antibodies prevented ADDLs binding to 
PrPC and were able to rescue synaptic plasticity in 
hippocampal slices. The deletion of 11 amino acids 
resulting in the Δ95–105 variant, significantly reduced 
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this binding [37]. After this first finding, other studies 
confirmed PrPC-mediated Aβ oligomer neurotoxic 
effects [19,34,35,40–46,108-110] while others have 
shown Aβ oligomer deleterious effects which seem not 
to require PrPC [47–50].
3.3 PrPC-mediated Aβ oligomer toxicity
Further investigations published also by authors who initi-
ally described PrP-independent Aβ toxicity, supported the 
role of PrPC in mediating at least part of Aβ oligomer 
detrimental effects, suggesting that a consensus may be 
forming. Transgenic mice expressing increasing amounts 
of Aβ on a PRNP null background presented no detectable 
impairment of spatial learning and memory, despite dis-
playing pathological levels of Aβ accumulation [108]. Basic 
amino acids 23–27 (KKRPK) at the very N-terminus of 
PrPC were identified as a relevant Aβ oligomer binding site 
in addition to the previously characterized region encom-
passing residues 92–110 [40]. The toxic effect of ex vivo 
material extracted from human AD brain was absent in 
hippocampal slices devoid of PrPC. Furthermore, the anti- 
PrP antibodies ICSM-35 (which recognizes an epitope 
within the residues 93–102) and ICSM-18 (recognizing 
residues 143–153) were both able to block the Aβ- 
mediated inhibition of LTP in vivo and in vitro [35]. Co- 
cultures of SH-SY5Y cells expressing PrPC with engineered 
CHO cells secreting toxic Aβ species in the culture med-
ium, led to a significant increase in apoptotic cell death in 
SH-SY5Y cells transiently expressing PrPC, while control 
SH-SY5Y cells expressing GPI-anchored GFP displayed no 
adverse effects on cell viability [43]. Interestingly, SH-SY5Y 
cells expressing PrPC did not exhibit increased apoptosis 
when co-cultured with CHO cells pre-treated with a γ- 
secretase inhibitor, showing that the detrimental effect was 
effectively driven by the presence of Aβ oligomeric toxic 
species in the culture medium. In the same study, they 
observed that toxic signalling via PrPC required its intrin-
sically disordered N-terminal domain and the GPI anchor. 
Interestingly, a secreted version of PrP N-terminal domain 
was able to associate with Aβ conformers and to antagonize 
their toxic signalling [43]. Additional studies showed that 
soluble Aβ extracted from AD brains was able to bind to 
PrPC at neuronal dendritic spines in vivo and in vitro where 
it formed a complex with fyn kinase, resulting in the 
activation of fyn activity. Furthermore, using the anti-PrP 
6D11 antibody to prevent Aβ oligomer binding to PrPC, 
they abolished fyn activation and fyn-dependent down-
stream effects [110]. In the attempt to identify and char-
acterize active PrP-dependent, PrP-independent and 
benign Aβ oligomeric assemblies, another study showed 
that Aβ assemblies that trigger PrPC-mediated toxicity are 
protofibrils with a defined three-dimensional structure 
[42]. The examined in vitro produced Aβ42 protofibrils 
presented an elaborated nanotube architecture with a triple 
helix structure wound around an hollow core [42].
3.4 PrPC proteolytic cleavage and its role in AD 
pathology
Full-length PrPC was able to inhibit in vitro Aβ40 and 
Aβ42 fibre formation and to cause disassembly of pre- 
formed Aβ mature fibrils, trapping Aβ in an oligomeric 
form enriched in antiparallel β-sheet [46]. Aβ recognition 
sites mapped to specific residues in the natively unstruc-
tured N-terminal half of PrPC, confirming the observa-
tions of previous studies pointing at residues 95–110 and 
23–27 as primary and secondary binding enhancement 
regions. Accordingly, this interaction would maintain Aβ 
in a more toxic oligomeric conformation and thus pro-
mote pathology [46]. In contrast with these results, several 
studies have shown an in vitro and in vivo protective role 
for the released full-length recombinant PrP and its 
N-terminal fragment [34,45,96,97]. PrPN1, the main phy-
siological cleavage fragment of PrPC, protected cultured 
primary neurons against toxicity and cell death triggered 
by oligomer-enriched conditioned medium collected 
from a CHO cell line overexpressing a mutated βAPP 
gene [97]. PrPN1 also protected neurons against oligo-
mers extracted from AD affected brain tissues [97]. The 
demonstration that PrPN1 was also able to bind early 
Aβ42 oligomeric intermediates during Aβ42 polymeriza-
tion into amyloid fibrils [34] confirmed that PrPC binding 
affinity is determined by positively charged residues in the 
two previously identified Aβ42 oligomer binding sites 
(positions 23–31 and 95–105). Interestingly, N1 strongly 
suppressed Aβ42 oligomer toxicity in cultured murine 
hippocampal neurons, in a Caenorhabditis elegans-based 
assay, and in vivo in a mouse model of Aβ-induced 
memory dysfunction [34]. Altogether these data suggest 
that PrPC cleavage processing may play a relevant role in 
modulating AD pathology. This hypothesis was verified 
in the APPswe/PSen1ΔE9 mouse model of AD, which 
showed altered PrPC processing characterized by 
increased levels of both α- and β-cleavage in brain cortex 
[98]. Since the released N1 fragment contains the 
N-terminal part of the protein which is thought to interact 
with pathological oligomers, the observed increase in α- 
processing could be interpreted as a protective response 
with two potential beneficial functions: i) to decrease 
PrPC-mediated toxic signalling reducing the presence of 
PrPC on the cell surface; ii) to neutralize Aβ oligomer 
pathological species before their binding to down-stream 
receptors [92]. On the other hand, the increase in β- 
cleavage, which has been previously associated to an 
excess of reactive oxygen species (ROS) [111], could 
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reflect distinct processes such as lysosomal failure to clear 
Aβ aggregates and/or increased ROS production induced 
by stress, which is a common feature in AD mouse models 
[98]. Interestingly, other reports described a protective 
role against cytotoxic Aβ42 oligomers of soluble (mem-
brane anchor-free) recombinant human prion protein 
(recHuPrP) and of the N1 fragment, also independently 
of the presence of endogenous PrPC [96]. Both recHuPrP 
and N1 blocked Aβ42 oligomer mediated inhibition of 
LTP in hippocampal slices and in WT primary hippo-
campal neurons. Furthermore, they reduced Aβ42 oligo-
mer-induced cytotoxic effects when the experiment was 
performed with hippocampal slices and neurons derived 
from PRNP null mice [96]. The authors explained these 
results suggesting a double protective action of recHuPrP 
and N1. The first mechanism would specifically target the 
PrPC-dependent LTP impairment, likely through 
a competitive inhibition of Aβ42 oligomer binding to 
PrPC on the membrane surface. A second, less specific 
protective role against cytotoxicity, might be due to 
recHuPrP and N1 interference in the interaction between 
Aβ and the cell membrane: recHuPrP and N1 would bind 
to Aβ42 oligomer species, or to the membrane surface, in 
a manner that prevents the formation of defects and/or 
pores in the lipid bilayer of cell membrane [96]. These 
hypothesized mechanisms were supported by another 
study which analysed chemically cross-linked small oli-
gomeric species of Aβ42, finding that recHuPrP inhibited 
the cytotoxicity of these species in neurons as well as their 
membrane permeation effects in liposomes [45]. Another 
recent study also supported a protective role of the N1 
fragment and investigated the potential beneficial effect of 
monoclonal antibodies grafted with one of the two PrP- 
Aβ oligomer binding sites (i.e. aa 19–33 or 87–112) [41]. 
PrP-grafted antibodies bound a significant portion of 
aggregated Aβ in aqueous AD extracts, but when these 
antibodies were co-incubated with neurons treated with 
brain extracts, they did not reduce toxicity. By contrast, 
PrP fragment N1 did protect against Aβ toxicity [41]. 
Since conversely to N1, the two grafted antibodies har-
boured only one binding sequence each, this suggested 
that the presence of both Aβ oligomers binding sites on 
the molecule was a requisite for the PrP-mediated protec-
tive role [41].
3.5 PrPC mediators of Aβ oligomer induced toxic 
signalling
It has been suggested that PrPC may mediate cell sig-
nalling as an extracellular scaffolding protein, able to 
organize multiprotein complexes at the cell surface 
[72]. Several studies suggested that this scaffolding 
could also lead to neurotoxic effects. For instance, 
PrPC binding to Aβ oligomers seems to produce 
a toxic signalling via metabotropic glutamate receptor 
5 (mGluR5) [112], which in turn, initiates multiple 
changes in synaptic homoeostasis, leading to excitotoxi-
city, endoplasmic reticulum stress, and, eventually, to 
synaptic degradation and neuronal cell death 
[37,98,108,110,113–116]. Furthermore, PrPC presence 
is enriched in post-synaptic densities (PSD) where the 
binding with in vitro and ex vivo derived Aβ oligomeric 
species activates the nonreceptor tyrosine kinase fyn, 
leading to NR2B phosphorylation and altered NMDAR 
localization and, ultimately, to destabilization of den-
dritic spines [44]. A mimicking peptide for the binding 
site of laminin γ1 to PrPC (Ln-γ1), induced intracellular 
Ca2+ increase in neurons via the complex PrPC- 
mGluR5 [109]. Even if Ln-γ1 promoted the internaliza-
tion of PrPC and mGluR5 and transiently decreased Aβ 
oligomer binding to neurons, the peptide did not 
impact Aβ oligomer toxicity [109]. Since mGluR5 
showed a key role in the transmission of toxic signal-
ling also in prion diseases, the same group tested 
whether mGluR5 knock-out mice would be susceptible 
to prion infection, observing mild, but significant, 
effects on disease progression (i.e. delay in disease 
onset), without affecting survival of infected mice [109].
4. PrPC-mediated tau toxicity
4.1 Tau neurotoxic species
Tau is a microtuble-associated protein that under phy-
siological conditions regulates microtubules assembly, 
dynamics and spatial organization [117]. The gene 
encoding tau, MAPT, is located on chromosome 
17q21.3, spans approximately 150 kb and consists of 16 
exons, only some of them constitutively translated [118]. 
Exons 2, 3 and 10 are subject to alternative splicing in the 
adult brain, giving rise to different tau isoforms that 
range from 37 to 46 kDa [119]. Interaction between tau 
and its partner, tubulin, is mediated by four imperfect 
repeat domains (encompassing 31–32 residues) encoded 
by exons 9–12 [120]. Alternative splicing of exon 10 
results in the production of isoforms containing either 
3 or 4 binding domains (3 R and 4 R tau) [121]. 
Tauopathies have as a common feature the accumulation 
of insoluble tau aggregates, called neurofibrillary tangles 
(NFTs), in the cell bodies of neurons and glia. Tau 
pathological aggregates differ in both phosphorylation 
and content of tau isoforms, which allows a molecular 
classification of tauopathies [4]. Recent evidence has 
implicated soluble, diffusible tau oligomers as important 
drivers of synaptotoxicity [21,29,117,122–124]. With the 
use of a tau oligomer-specific antibody, T22, it has been 
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found that tau oligomers in human AD brain samples are 
four-fold higher than those in control brains and that tau 
oligomers are present in early stages of AD cytopathology 
[122]. Post-mortem analysis of brains from subjects 
affected by mild cognitive impairment have shown that 
cognitive decline was related with pre-fibrillar tau rather 
than NFTs [125,126] and several tau transgenic animal 
models have shown behavioural deficits, synaptic dys-
function, and cell death in the absence of NFTs forma-
tion [124]. Exogenous application of in vitro obtained 
soluble tau aggregates and tau oligomers extracted 
from AD brains impaired hippocampal LTP in vitro, 
and memory in mice [21,122]. Interestingly, tau oligo-
mers could also act in combination with Aβ oligomers to 
produce these detrimental effects, since sub-toxic doses 
of the two species, administered in combination, led to 
LTP and memory impairment [21]. The same group 
observed that APP expression was required for an effi-
cient intra-neuronal uptake of Aβ and tau oligomers [29]. 
Furthermore, APP-null mice were resistant to Aβ and tau 
oligomer induced impairment in memory and LTP, sug-
gesting that the toxic effect was dependent upon APP 
expression [29].
4.2 PrPC-mediated tau oligomer toxicity
Since PrPC has been identified as a receptor for PrPSc and 
Aβ oligomers (see above), recently many investigations 
have explored the interaction between PrPC and other 
prion-like aggregated species. So far, few studies have 
shown a potential crosstalk between PrPC and tau aggre-
gates [19,23,52,53,127]. The possibility of an interaction 
between tau and PrPC was already suggested by neuro-
pathological examination of GSS cases which displayed 
the presence of co-pathology of PrPSc with hyperpho-
sphorylated forms of tau [56–63]. Furthermore, full- 
length recombinant tau has been reported to bind to 
recombinant PrPC, in vitro [128]. In details, the 
N-terminus (amino acids 1–91) and tandem repeats 
region (amino acids 186–283) of tau were shown to be 
responsible for the interaction, which involved the octa-
peptide repeat domain on PrPC. The P102L GSS-related 
mutant and other PrPC mutants characterized by the 
presence of two or seven extra octapeptide repeats (asso-
ciated with familial forms of prion disorders) have shown 
enhanced tau binding affinity compared to WT PrPC 
[128]. The first study showing a PrPC-mediated causality 
of tau oligomers, investigated the neurotoxic effect of 
secretomes of human induced pluripotent stem cell 
(iPSC)-derived models of AD [53]. In this study it was 
observed that the secretome of iPSC-derived neurons 
harbouring trisomy of chromosome 21 (Ts21secretome) 
was enriched in a complex mixture of extracellular tau 
species capable of inducing in vivo LTP impairment. 
Furthermore, they observed that this detrimental effect 
was prevented by tau immunodepletion of the Ts21 secre-
tome or by pre-injection of the anti-PrP 6D11 antibody 
[53]. They presented comparable results using Aβ oligo-
mer enriched secretomes of other iPSC-derived neuronal 
cell lines harbouring mutations in APP or PS1 [53]. 
Intracerebroventricular injection of soluble aggregates 
formed from either WT or mutant P301S human recom-
binant tau potently inhibited hippocampal LTP in vivo, 
while tau monomers and end-stage fibrils appeared inac-
tive [23]. Moreover, AD brain soluble extracts inhibited 
LTP in a tau-dependent manner. Their effect on LTP was 
abolished by tau immunodepletion or co-injection of 
a mid-region anti-tau monoclonal antibody, Tau5 [23]. 
Antibodies against the mid-region (6D11) and the 
N-terminus (MI-0131) of PrPC, also prevented the LTP 
inhibition induced by both recombinant and brain- 
derived tau, confirming a PrPC-mediated tau toxic effect 
[23]. Recently, another study provided evidence that solu-
ble aggregates of tau bind to PrPC in vitro and on mouse 
cortical neurons, via N-terminal PrPC Aβ oligomer bind-
ing sites [19]. Tau soluble aggregates (produced in vitro or 
extracted from diseased brains) caused both functional 
(impairment of LTP) and structural (neuritic dystrophy) 
effects prevented by PrPC ablation or pre-treatment with 
anti-PrPC blocking antibodies [19]. In this study Corbett 
and colleagues proposed a standardized protocol to 
obtain soluble aggregates of tau (and also of Aβ and α- 
syn) which were isolated by progressive steps of centrifu-
gation and sonication from in vitro obtained end-stage 
fibrils or by ultracentrifugation of brain homogenates and 
collection of their supernatant fractions [19].
4.3 PrPC mediates tau uptake and complex 
tau-induced effects
Conversely to Aβ oligomers, in vivo injection of soluble 
full-length tau aggregates, increased the threshold for 
long-term depression (LTD) induction [127]. This 
effect was mediated by PrPC and was reduced by sys-
temic treatment with Ro 25–6981, a selective antagonist 
of GluN2B subunit-containing NMDA receptors [127]. 
Interestingly, the same molecule was not able to pre-
vent tau-induced PrPC-mediated LTP. When co- 
administered with Aβ oligomers, tau soluble aggregates 
exhibited complex effects towards Aβ oligomer 
mediated LTD and LTP, completely blocking Aβ- 
facilitated LTD, while facilitating Aβ-induced LTP 
[127]. Taken together, these results suggested that 
both tau and Aβ oligomeric species interact with PrPC 
to elicit opposite effects on synaptic plasticity, probably 
mediated by different effectors [127]. A complex 
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interplay between PrPC and tau fibrils has been recently 
shown. Fibrils of tau K18 (i.e. a truncated form of 
human tau containing only the 4 microtubule binding 
repeats) were actively internalized by N2a cells via PrPC 
[52]. The uptake of tau K18 fibrils was reduced in 
PrPC-knockout N2a cells and by pre-treatment with 
antibodies against the N-terminus of PrPC. 
Surprisingly, exposure of ScN2a cells (i.e. chronically 
prion-infected N2a cells) to tau K18 fibrils, reduced 
PrPSc levels and increased PrPC α-cleavage [52]. The 
study proposed that tau-induced clearance of PrPSc 
could be related to either an increase in PrPC proces-
sing or to a direct binding of tau fibrils to PrPC, ulti-
mately impeding its conversion in PrPSc. These data 
suggest a bidirectional interaction between the two 
proteins [52].
5. PrPC-mediated α-synuclein toxicity
5.1 α-synuclein neurotoxic species
Synucleopathies are defined by the abnormal aggrega-
tion of α-syn with symptoms and clinical manifesta-
tions ranging from motor alterations to 
neuropsychiatric disturbances, cognitive decline and 
memory impairment [129]. LB pathology is not only 
confined to the substantia nigra, but extends to multi-
ple brain areas including hippocampus and cortex, 
explaining the presence of non-motor symptoms 
[130,131]. Recent studies suggested that, as for other 
neurodegenerative diseases, α-syn oligomers may repre-
sent the most toxic α-syn species which, once released 
from neuronal cells, could contribute to the spread of 
pathology and, ultimately, to the major pathological 
features of α-synucleinopathies [32]. Extracellular α- 
syn oligomers, but not monomers or fibres, showed 
a detrimental effect on hippocampal LTP and increased 
basal synaptic transmission, through a mechanism 
dependent on NMDA receptor activation [30]. 
Furthermore, extracellular α-syn released from neuro-
nal cells, was shown to bind to the Toll-like receptor 2 
(TLR2), which, in turns, activated inflammatory 
responses in microglia, leading, eventually, to 
a neuroinflammatory response [31]. Interestingly, only 
specific types of α-syn oligomers were able to interact 
with and activate TLR2, suggesting that this α-syn- 
mediated TLR2 activation was conformation-sensitive 
[31]. Finally, Mao and colleagues suggested that the 
transmembrane protein, lymphocyte-activation gene 3 
(LAG3/CD223) could be a neuronal receptor for syn-
thetic α-synuclein preformed fibrils (PFF). Depletion of 
LAG3, or antibodies against LAG3, substantially 
reduced the transmission and consequent neurotoxicity 
of pathologic α-syn PFF [132]. In the last years, several 
studies described, sometimes with conflicting results 
[55], a number of α-syn toxic effects and mechanisms 
of inter-neuronal transmission, mediated, at least in 
part, by the cellular prion protein [19,22,51,133], 
which will be discussed in the next paragraph.
5.2 PrPC-mediated α-syn toxicity and uptake
Initial studies involving PrPC in α-syn propagation and 
toxicity, compared the spreading and the extent of α-syn 
pathology in Prnp+/+, Prnp0/0 and Tga20 (i.e. overexpres-
sing PrPC) mice injected, in the striatum, with α-syn PFF 
[133]. Prnp expression was not mandatory for α-syn 
transport in the mouse brain, although Prnp+/+ and 
Tga20 mice displayed increased levels of α-syn transport. 
Tga20 mice also showed increased Lewy body-like pathol-
ogy in motor pyramidal neurons [133]. The same year, 
another independent study confirmed that PrPC overex-
pression enhanced α-syn spreading and its pathologic 
deposition in vitro and in vivo [51]. Several studies 
observed α-syn binding sites on PrPC [19,22,54] see-
mingly corresponding to the previously described PrPC 
Aβ oligomer high affinity binding regions [40,46]. 
HEK293 cells expressing a PrPC mutant devoid of its 
central domain (i.e. aa 90–110 or aa 91–115) presented 
significantly lower binding affinity for α-syn PFF [133] 
and α-syn oligomer mediated detrimental effect on LTP 
was abolished in hippocampal slices pre-treated with 
6D11 anti-PrP antibody [22]. Very recently, another 
study has shown that Aβ, tau and α-syn protofibrils 
induced neurotoxic effects via PrPC and their interaction 
was mediated by the two previously described Aβ oligo-
mer binding site I (aa 23–33) and II (aa 88–111) [19]. 
Additional studies investigated putative effectors of α-syn 
oligomer-induced impairment of LTP and demonstrated 
that α-syn oligomers physically interacted with PrPC, 
inducing the phosphorylation of Fyn kinase via mGluR5 
with the consequent activation of the NMDAR subunit 2B 
and altered calcium homoeostasis [22]. Notably, mGluR5 
has been already described as a PrPC binding partner in 
the transmission of Aβ oligomer-induced toxic signalling 
[109,112]. In contrast, another study, found that PrPC was 
not mandatory to mediate α-syn oligomer detrimental 
effects in vitro and in vivo [55]. α-syn oligomer toxicity 
was comparable in Prnp+/+ and Prnp0/0 neurons and both 
Prnp+/+ and Prnp0/0 mice injected with α-syn oligomers 
presented memory deficits and hippocampal gliosis. 
Furthermore, surface plasmon resonance experiments 
showed no interaction between PrPC and the preparation 
employed of α-syn oligomers [55]. These latter results 
suggest that further experiments are needed to address 
the relationship between PrPC and α-syn pathological 
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species. As for Aβ oligomers, it is possible that different 
pathological conformers influence the binding with PrPC 
and drive PrPC-independent toxic effects. To clarify this 
point and to evaluate the significance of PrPC in α- 
synucleinopathies, it is of utmost importance to extend 
the characterization and to standardize the preparation 
protocols of tested aggregates, as recent studies have 
pointed out [19]. As for tau, also α-syn fibrils presented 
a surprising effect on prion clearance in an in vitro cellular 
system [51]. When fibrils of α-syn were added to N2a cells 
chronically infected with prions, they induced a reduction 
in the levels of the PK-resistant PrPSc material and an 
increase in PrPC α-cleavage processing, confirming that 
the interplay between pathological proteinaceous aggre-
gates and PrPC could involve bidirectional effects [51,52].
6. Conclusions and future perspectives
The interaction between PrPC and Aβ toxic oligomeric 
species seems now widely accepted. As a consequence, 
several studies have extended their focus to validate the 
hypothesis that PrPC mediates the uptake and the toxic 
signalling induced by aggregates of proteins other than 
Aβ, such as tau and α-synuclein. PrPC interaction with 
these toxic species seemingly involves complex mechan-
isms of signal transduction and is likely influenced by 
PrPC physio-pathological cleavage processing. Moreover, 
initial reports suggested that the interplay between PrPC 
and pathological aggregates could lead to bidirectional 
effects. Figure 1 schematically illustrates the major pro-
posed PrPC-mediated effects discussed in this review. 
Lessons learned from the first studies on PrPC and Aβ 
interaction could be used as a guide to design future 
investigations and to correctly interpret resulting data. 
First of all, it is now clear that the preparation protocol 
used to obtain synthetic aggregates is a key element to 
increase the reproducibility of results and to help in the 
characterization of the putative pathological conformer 
responsible for PrPC-mediated toxic effects. Related to 
this point, patient-derived Aβ, tau and α-syn enriched 
samples are extremely precious, and it would be reason-
able to collect data on in vitro obtained aggregates and to 
subsequently verify their biological relevance as a second 
step. A second point is that studies should report both 
positive and negative results, which should help to under-
stand the mechanistic processes involved in the transmis-
sion of toxicity. Faster understanding of the biological 
significance and central role of PrPC for many neurode-
generative disorders may have relevant therapeutic impli-
cations. If the nature and extent of the interaction 
between PrPC and neurodegenerative pathological aggre-
gates will be confirmed, PrPC could be the target of 
several therapeutic approaches, as for instance the use 
of antisense oligonucleotides to knock-down the PRNP 
gene via RNA interference, the administration of PrPC 
derivatives (i.e. the full-length recombinant protein or its 
N-terminal fragment) or anti-PrPC antibodies. In this 
regard it should be mentioned that the use of anti-PrPC 
antibodies in therapeutic applications might be limited to 
avoid undesired detrimental effects due to the disruption 
of physiologically relevant and protective PrPC 
interactions.
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